Bioprocessing Equipment Market Size & Share 2026-2035

Bioprocessing Equipment Market Size

The global bioprocessing equipment market was valued at USD 48.1 billion in 2025 and is projected to grow from USD 53.5 billion in 2026 to USD 152.2 billion by 2035, expanding at a CAGR of 12.3%, according to the latest report published by Global Market Insights Inc. The steady growth of the market is driven by the growing adoption of single-use bioprocessing systems, rising demand for biologics and biosimilars, rapid expansion of cell and gene therapy manufacturing and increasing outsourcing to CMOs and CROs accelerating equipment procurement cycles, among other factors.

The major players in the global market are Danaher, Sartorius AG, Merck, Thermo Fisher Scientific, and Repligen Corporation. These companies maintain their competitive position through consistent product innovation, investment in R&D activities, global market presence, and collaboration with healthcare facilities, among others.

The market increased from USD 34 billion in 2022 to USD 42.8 billion in 2024, registering a historical growth rate of 13.2%. The rapid growth of cell and gene therapy development is creating significant demand for specialized bioprocessing equipment. These therapies involve highly complex manufacturing processes that require precise environmental control, advanced cell culture systems, and scalable production technologies. As increasing numbers of cell and gene therapies advance through clinical and commercial stages, manufacturers are investing in dedicated facilities equipped with sophisticated bioprocessing solutions. The need for maintaining product consistency, sterility, and regulatory compliance further supports demand for advanced equipment.

Additionally, the adoption of single-use bioprocessing systems is accelerating market growth by providing manufacturers with greater operational flexibility and lower infrastructure costs. Disposable bioreactors, mixers, tubing, and filtration systems eliminate the need for extensive cleaning and sterilization processes, reducing downtime and operational complexity. These systems also minimize cross-contamination risks, which is particularly important in multi-product manufacturing environments. Furthermore, lower capital investment requirements allow biotechnology companies and contract manufacturers to expand production capacity more rapidly.

Furthermore, biopharmaceutical companies are increasingly outsourcing manufacturing and development activities to contract manufacturing organizations (CMOs) and contract research organizations (CROs) to reduce costs, access specialized expertise, and accelerate product commercialization. To accommodate growing client demand, CMOs and CROs are expanding production facilities and investing in advanced bioprocessing equipment. As outsourcing becomes a preferred strategy across the biopharmaceutical sector, equipment procurement cycles are accelerating, resulting in higher demand for bioreactors, filtration systems, chromatography solutions, and automated process control technologies.

Bioprocessing equipment refers to the specialized instruments, systems, and technologies used in the production of biologics, vaccines, biosimilars, cell therapies, and other biopharmaceutical products. These equipment solutions support upstream and downstream processes such as cell culture, fermentation, etc., helping manufacturers ensure product quality, operational efficiency, scalability, and regulatory compliance throughout biomanufacturing operations.

Bioprocessing Equipment Market Trends

Growing adoption of single-use technologies (SUTs), integration of automation and digitalization, expansion of cell and gene therapy manufacturing, shift toward continuous bioprocessing, and rising focus on modular and flexible manufacturing facilities are among the key trends shaping the market growth in an upward trajectory.

• Bioprocessing facilities are increasingly incorporating automation, artificial intelligence, and real-time monitoring solutions to improve process efficiency and consistency. Advanced control systems enable better data collection, predictive maintenance, and process optimization, helping manufacturers improve yields, reduce production errors, and enhance overall operational performance.
• Additionally, the increasing use of single-use bioprocessing equipment is transforming biomanufacturing operations by reducing cleaning requirements, minimizing contamination risks, and improving operational flexibility. Biopharmaceutical manufacturers are increasingly adopting disposable bioreactors, mixers, and filtration systems to accelerate production timelines and lower capital expenditures, particularly for small-batch and multi-product facilities.
• Further, continuous bioprocessing is gaining traction as companies seek higher productivity and cost efficiency. Unlike traditional batch processing, continuous manufacturing enables uninterrupted production, improves product consistency, reduces facility footprints, and supports faster scale-up, making it an attractive approach for modern biopharmaceutical manufacturing facilities.

Bioprocessing Equipment Market Analysis

Based on product type, the market is segmented into bioreactors, filtration systems, chromatography systems, mixing systems, centrifuges, cell culture systems, control and monitoring systems, and other product types. The bioreactors segment held a leading market share and was valued at USD 13.3 billion in 2025.

• Bioreactors represent one of the most critical segments of the bioprocessing equipment market, as they are used for cultivating microorganisms, mammalian cells, and other biological materials under controlled conditions. Demand for bioreactors is increasing due to the growing production of biologics, biosimilars, vaccines, and advanced therapies.
• Additionally, manufacturers are increasingly adopting single-use and hybrid bioreactor systems that offer flexibility, faster turnaround times, and reduced contamination risks.
• Technological advancements such as automated monitoring, real-time process control, and scalable designs are further enhancing their adoption.
• Furthermore, the expansion of cell and gene therapy manufacturing is also contributing to the growing demand for specialized bioreactor solutions.
• The filtration systems segment accounted for USD 11.3 billion in 2025. Filtration systems play a vital role in biopharmaceutical manufacturing by supporting cell separation, clarification, concentration, and purification processes.
• Growing production volumes of biologics and vaccines are driving demand for efficient filtration technologies that can improve yield and product quality. Manufacturers are increasingly adopting advanced membrane filtration systems, including ultrafiltration and microfiltration solutions, to enhance process efficiency.
• Moreover, as regulatory expectations for product purity continue to rise, filtration systems remain essential components of modern bioprocessing facilities.
• The chromatography systems segment accounted for USD 8.7 billion in 2025 and is projected to grow at a robust CAGR over the forecast period. Chromatography systems are widely used in downstream processing for the purification and separation of biological molecules such as proteins, antibodies, and vaccines.
• In addition, the increasing complexity of biologic drugs is driving demand for high-performance chromatography solutions capable of delivering superior product purity and recovery rates.
• Manufacturers are investing in advanced resins, automated systems, and continuous chromatography technologies to improve operational efficiency.
• Further, the growing production of monoclonal antibodies and cell-based therapies further supports demand for chromatography equipment.

Based on process, the global bioprocessing equipment market is segmented into upstream processing and downstream processing. The upstream processing segment is projected to expand at a 12.1% CAGR to reach USD 87.5 billion by 2035.

• Upstream processing involves the initial stages of biopharmaceutical production, including cell line development, media preparation, cell cultivation, and fermentation. This segment is experiencing strong growth due to increasing investment in biologics, biosimilars, vaccines, and advanced therapies.
• In addition, demand for bioreactors, cell culture systems, media preparation equipment, and process monitoring tools continues to rise as manufacturers focus on improving productivity and consistency.
• Moreover, growing emphasis on reducing development timelines and increasing manufacturing flexibility is further driving investment in upstream processing equipment.
• The downstream processing segment is projected to expand at a 12.6% CAGR to reach USD 64.7 billion by 2035. Downstream processing involves the recovery, purification, and formulation of biological products after cell cultivation. This segment accounts for a significant share of bioprocessing activities because it directly impacts product quality, purity, and regulatory compliance.
• Increasing production of high-value biologics and monoclonal antibodies is driving demand for filtration, chromatography, and separation technologies.
• Additionally, the adoption of continuous processing technologies and automated purification systems is further strengthening the importance of downstream processing within the overall biopharmaceutical manufacturing workflow.

Based on application, the global bioprocessing equipment market is segmented into monoclonal antibodies (mAbs), vaccines and immunotherapy, cell and gene therapy, recombinant proteins and enzymes, biosimilars, and other applications. The monoclonal antibodies segment is projected to expand at an 11.9% CAGR to reach USD 55.7 billion by 2035.

• Monoclonal antibodies represent a major application area for bioprocessing equipment due to their widespread use in treating cancers, autoimmune diseases, and chronic conditions.
• Large-scale manufacturing of mAbs requires sophisticated upstream and downstream processing equipment to ensure high yields and product consistency.
• Additionally, growing demand for antibody-based therapeutics and biosimilars is encouraging biopharmaceutical companies to expand production capacity. This trend is generating strong demand for bioreactors, filtration systems, chromatography platforms, and process analytics solutions.
• Further, continuous innovation in antibody development is expected to support long-term growth within this application segment.
• The vaccines and immunotherapy segment is projected to expand at a notable growth to reach USD 8.7 billion by 2035. The vaccines and immunotherapy segment is a significant contributor to demand for bioprocessing equipment.
• Increasing efforts to develop preventive and therapeutic vaccines, along with advancements in immunotherapy, are driving investments in biomanufacturing infrastructure.
• Manufacturers are adopting advanced technologies to improve scalability, efficiency, and quality assurance.
• In addition, ongoing research into infectious diseases and immune-based treatments continues to create opportunities for bioprocessing equipment suppliers serving this dynamic healthcare segment.
• The cell and gene therapy segment accounted for USD 7 billion in 2025 and is projected to grow at the fastest CAGR over the forecast period. Cell and gene therapy is one of the fastest-growing application areas within the bioprocessing equipment market.
• Additionally, these therapies require specialized manufacturing processes involving cell expansion, genetic modification, and highly controlled production environments. Increasing clinical development activities and commercialization efforts are driving investments in advanced bioprocessing technologies.
• Moreover, demand is particularly strong for single-use systems, automated bioreactors, and process monitoring equipment capable of supporting small-batch, high-value production.

Based on end use, the market is segmented into biopharmaceutical and pharmaceutical companies, CMOs and CROs, and academic and research institutes. The biopharmaceutical and pharmaceutical companies segment held a leading market share of 63.1% in 2025.

• Biopharmaceutical and pharmaceutical companies constitute the largest end-user segment of the bioprocessing equipment market. These organizations continuously invest in advanced manufacturing technologies to support the production of biologics, vaccines, biosimilars, and emerging therapies.
• Growing product pipelines and increasing regulatory requirements are encouraging companies to upgrade existing facilities and build new manufacturing capacities. Demand for automated and scalable equipment is rising as manufacturers seek to improve efficiency, reduce production costs, and ensure product quality.
• Further, the increasing focus on innovation and large-scale commercial production continues to support strong equipment adoption.
• The CMOs and CROs segment is expected to show a high growth rate of 13% through 2035. Contract manufacturing organizations (CMOs) and contract research organizations (CROs) are becoming increasingly important end users of bioprocessing equipment.
• Rising outsourcing activities across the biopharmaceutical sector are driving these organizations to expand capacity and invest in flexible manufacturing technologies.
• CMOs and CROs require equipment capable of supporting multiple projects, diverse product types, and varying production scales. In addition, single-use systems, automated process controls, and scalable bioprocessing platforms are particularly attractive within this segment.
• Further, as outsourcing continues to grow, these service providers are expected to remain key contributors to overall demand for bioprocessing equipment.

North America Bioprocessing Equipment Market

The North America region accounted for 38% share of the global bioprocessing equipment industry in 2025. The market is experiencing robust expansion, driven by the region’s advanced healthcare infrastructure, supportive government funding for biotechnology research, growing prevalence of chronic diseases, and technological advancements in devices.

• The U.S. market was valued at USD 17.3 billion in 2025 from USD 15.5 billion in 2024.
• Additionally, a well-established network of contract development and manufacturing organizations (CDMOs) is driving demand for flexible and scalable bioprocessing equipment across the U.S. and Canada.
• North America represents a leading market for bioprocessing equipment, supported by a strong biopharmaceutical industry, advanced biotechnology research infrastructure, and substantial investments in biologics manufacturing.
• Biopharmaceutical companies are expanding manufacturing capacities and adopting advanced bioprocessing technologies to improve efficiency and regulatory compliance.
• Further, the growing use of single-use systems, automation platforms, and digital process monitoring solutions is further accelerating market development.

Europe Bioprocessing Equipment Market

Europe market accounted for USD 14.5 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• The European bioprocessing equipment industry is growing steadily due to strong pharmaceutical and biotechnology sectors, increasing biologics production, and continuous innovation in manufacturing technologies.
• Countries such as Germany, the UK, Switzerland, France, and Ireland serve as important biopharmaceutical production hubs, supporting demand for advanced bioprocessing systems. The region is witnessing increased adoption of continuous manufacturing, automation technologies, and single-use equipment to enhance productivity and sustainability.
• In addition, expansion of biosimilar development activities and rising investments in cell and gene therapy production facilities are also contributing to market growth.
• Furthermore, collaboration between biotechnology companies, research institutions, and equipment suppliers continues to support technological advancements throughout the region.

Asia Pacific Boprocessing Equipment Market

The Asia Pacific region is projected to show a lucrative growth of about 13.7% during the forecast period.

• Asia Pacific is emerging as one of the fastest-growing markets for bioprocessing equipment, driven by expanding biopharmaceutical manufacturing activities, increasing healthcare expenditures, and growing biotechnology investments.
• Countries such as China, India, South Korea, Japan, and Singapore are actively strengthening their biomanufacturing capabilities through facility expansions and technology upgrades. The increasing production of biosimilars, vaccines, and biologics is creating substantial demand for bioreactors, filtration systems, and process analytics equipment.
• Additionally, favourable government initiatives supporting biotechnology development and the growing presence of regional CDMOs are enhancing market opportunities.
• Moreover, the adoption of cost-effective manufacturing approaches and modern bioprocessing technologies is expected to further accelerate regional growth.

Latin America Bioprocessing Equipment Market

Latin America is experiencing significant growth in the market.

• The bioprocessing equipment industry in Latin America is expanding gradually, supported by growing pharmaceutical manufacturing activities and increasing investments in biotechnology infrastructure. Brazil and Mexico remain the primary contributors to regional growth due to their expanding healthcare sectors and rising demand for biologics and vaccines.
• Local manufacturers and healthcare institutions are increasingly investing in modern production technologies to improve manufacturing efficiency and product quality.
• Furthermore, increasing collaboration with international pharmaceutical firms and efforts to improve access to advanced therapies are creating additional opportunities for bioprocessing equipment suppliers across the region.

Middle East and Africa Bioprocessing Equipment Market

• The Middle East and Africa market is witnessing gradual growth as governments and healthcare organizations focus on strengthening pharmaceutical and biotechnology manufacturing capabilities.
• Rising interest in local biopharmaceutical production is driving demand for advanced bioprocessing technologies, including bioreactors, filtration systems, and process control equipment.

• Further, the region is also benefiting from partnerships with global biotechnology companies that support technology transfer and workforce development. As healthcare diversification strategies continue to advance, demand for modern bioprocessing solutions is expected to increase steadily across MEA.

Bioprocessing Equipment Market Share

The bioprocessing equipment industry exhibits a moderately consolidated competitive landscape, with a mix of established life sciences equipment manufacturers and specialized biotechnology solution providers competing across upstream, downstream, and process analytics segments. Leading companies such as Danaher, Sartorius, Merck, Thermo Fisher Scientific, and Repligen Corporation focus on expanding their product portfolios through innovation in bioreactors, filtration systems, chromatography equipment, cell culture technologies, and automation platforms to address evolving biopharmaceutical manufacturing requirements.

Additionally, competition is increasingly centered on the ability to provide integrated and scalable solutions that improve production efficiency, reduce contamination risks, and support regulatory compliance. Manufacturers are investing heavily in automation, digital monitoring, and data-driven process control technologies to enhance process reliability and optimize yields. The growing adoption of single-use technologies has also intensified competition, prompting companies to develop advanced disposable bioprocessing systems that offer flexibility and lower operational costs.

Further, strategic collaborations with biopharmaceutical companies, research institutes, and contract development and manufacturing organizations (CDMOs) have become common as suppliers seek to strengthen their market presence and support new therapeutic modalities such as cell and gene therapies. In addition, capacity expansions, regional manufacturing investments, and acquisitions remain key competitive strategies aimed at broadening geographic reach and technological capabilities.

Moreover, as demand for biologics, vaccines, and advanced therapies continues to grow, market participants are increasingly differentiating themselves through customized solutions, process efficiency, sustainability initiatives, and comprehensive service offerings, creating a dynamic and innovation-driven competitive environment.

Bioprocessing Equipment Market Companies

Few of the prominent players operating in the bioprocessing equipment industry include:

• ABEC Inc.
• Cellexus Ltd.
• Danaher
• Distek Inc.
• Eppendorf AG
• Getinge AB
• Lonza Group
• Merck
• PBS Biotech Inc.
• Pierre Guerin Technologies (SPX Flow)
• Repligen Corporation
• Sartorius AG
• Single Use Support GmbH
• Solaris Biotech (Donaldson)
• Thermo Fisher Scientific

Thermo Fisher Scientific leverages its broad product portfolio and global manufacturing network to provide comprehensive bioprocessing solutions. Its strategy includes capacity expansion, technology innovation, and support for biologics, vaccines, and cell and gene therapy production.

Repligen Corporation focuses on specialized bioprocessing technologies, particularly filtration, chromatography, and process analytics. The company drives growth through targeted acquisitions, product innovation, and partnerships that strengthen its position in high-value biopharmaceutical manufacturing applications.

The bioprocessing equipment market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Bioreactors
• Filtration systems
• Chromatography systems
• Mixing systems
• Centrifuges
• Cell culture systems
• Control and monitoring systems
• Other product types

Market, By Process

• Upstream processing
• Downstream processing

Market, By Application

• Monoclonal antibodies (mAbs)
• Vaccines and immunotherapy
• Cell and gene therapy
• Recombinant proteins and enzymes
• Biosimilars
• Other applications

Market, By End Use

• Biopharmaceutical and pharmaceutical companies
• CMOs and CROs
• Academic and research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE